Royce & Associates LP Mirati Therapeutics, Inc. Transaction History

Royce & Associates LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$59.49 - $104.71 $1.19 Million - $2.09 Million	-20,000 Closed	0 $0
Q1 2019 May 09, 2019	SELL	$43.65 - $78.95 $484,515 - $876,345	-11,100 Reduced 35.69%	20,000 $1.47 Million
Q3 2018 Nov 13, 2018	SELL	$47.1 - $62.7 $942,000 - $1.25 Million	-20,000 Reduced 39.14%	31,100 $1.47 Million
Q2 2018 Aug 09, 2018	SELL	$26.05 - $52.4 $260,500 - $524,000	-10,000 Reduced 16.37%	51,100 $2.52 Million
Q1 2018 May 14, 2018	SELL	$17.2 - $34.95 $1.03 Million - $2.1 Million	-60,000 Reduced 49.55%	61,100 $1.88 Million
Q4 2017 Feb 09, 2018	SELL	$12.65 - $19.0 $1.64 Million - $2.47 Million	-130,000 Reduced 51.77%	121,100 $2.21 Million
Q2 2017 Aug 07, 2017	BUY	N/A	251,100	251,100 $917,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.